RECENT NEWS
For Media Inquiries
Melissa Andrews, Director of Marketing
970-926-1277 / mandrews@cando-ms.org
Media Kit
This September, show the world how you #ThriveWithMS to inspire others and spread awareness of multiple sclerosis
August 28th, 2020
Can Do Multiple Sclerosis, a non-profit that delivers health and wellness education programs for families with MS, launched their annual, online campaign today that encourages people living with MS, as well as their friends and supporters, to share how they thrive with MS during September’s Can Do Month celebration.
Color Street Foundation pledges $100,000 to support MS awareness
August 10th, 2020
For the month of August, the Color Street Foundation is pledging $100,000 to support awareness, research, and direct support programs for those who live with MS.
Continue Reading
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
June 1st, 2020
ROCKLAND, Mass., May 27, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced today the U.S. Food and Drug Administration (FDA) has approved the inclusion of new safety data on pregnancy and breastfeeding in the prescribing information for Rebif® (interferon beta-1a), in accordance with the FDA's Pregnancy and Lactation Labeling Rule (PLLR).
Continue Reading
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA®
June 1st, 2020
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that ZEPOSIA® (ozanimod) 0.92 mg, a new once-daily oral medication for adults for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, is now commercially available in the U.S. ZEPOSIA was approved by the U.S. Food and Drug Administration (FDA) on March 25, 2020.
Continue Reading
New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis
April 28th, 2020
Post-hoc analysis from 6 years of Phase III open-label extension studies showed Ocrevus treatment reduced the risk of needing a walking aid (EDSS≥6) by 49% in relapsing multiple sclerosis (RMS) patients compared with patients who switched from interferon beta-1a two years later
Continue Reading
Art Alexakis Releases Poignant Music Video for Multiple Sclerosis-Inspired Song “The Hot Water Test”
April 27th, 2020
Art Alexakis, the charismatic frontman of multi-platinum selling rock band, Everclear, is premiering the music video for his multiple sclerosis (MS)-inspired song, “The Hot Water Test”.
Continue Reading
Reflections on MS Global, "Personal Best," and Biking With MS
November 1st, 2019
The bike is an ideal metaphor and symbol for all of us facing the many-layered challenges of MS. “Believe in the power of the bike” is the slogan of MS Global, a band of sisters and brothers who get together every year to ride (a long way) in lovely places to raise money and awareness for people living with MS.
Can Do MS Receives Highest Recognition from Charity Navigator
October 1st, 2019
Thanks to its sound fiscal management practices and commitment to accountability and transparency, Can Do Multiple Sclerosis (Can Do MS) has earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.
Continue Reading
Can Do Multiple Sclerosis Announced as Benefactor for 11th Annual Man of the Cliff
September 25th, 2019
Man of the Cliff Returns to Avon's Nottingham Park October 12-13, 2019: Announces Can Do Multiple Sclerosis as Benefactor for 11th Annual Event
Continue ReadingWhat’s Top of Mind for People with Multiple Sclerosis?
September 15th, 2019
New Research from Can Do MS and EMD Serono Identifies Financial Planning and Staying in the Workplace as Critical Concerns in Managing Unpredictable Disease
Continue Reading